rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Amerikaanse aandelen Terug naar discussie overzicht

intercloud--icld

429 Posts
Pagina: «« 1 ... 12 13 14 15 16 ... 22 »» | Laatste | Omlaag ↓
  4. [verwijderd] 13 februari 2016 17:39

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Het is je gegund jager ik ga met vrx ook dagritjes doen als ik mijn verlies.
    Wat beperkt heb zit er in op 94.7.
    Maar heb er ook wat moeten verkopen met verlies.
    Om degiro tevreden te houden
  5. [verwijderd] 13 februari 2016 21:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    There are few things that have gone right for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) over the past few months. Just a short six months ago the company was the best-performing stock on the market with one of the largest market caps.

    There’s a lot that has changed within and related to Valeant in the past few months. Here’s a review of what has changed and how it impacts investors.

    Valeant’s stock has dropped faster than the market has

    Over the course of the past six months the stock has dropped nearly 65%. While stocks rise and fall on a daily basis, Valeant’s peak made it the largest company on the TSX by market cap, which makes the collapse of the stock that much more significant to investors.

    One of the many quotes by Warren Buffett that is often repeated is “be fearful when others are greedy, and greedy when others are fearful.” This quote couldn’t be further from the truth for Valeant, and investors wondering if they should invest in the company should ask themselves whether they are fearful or greedy.

    So in other words, at the current price Valeant can be purchased at a bargain, but is the investment worth the risk? There are those that see the company as a large risk, and then there are those that see this as an opportunity to double down and purchase more shares.

    Valeant’s business model has drawn a lot of attention

    Valeant is well known as a company that grows primarily through acquisitions. More than 100 companies have been acquired by Valeant over the past seven years. What happens once Valeant acquires those companies is what has been the subject of much debate and attention lately.

    The company has come under fire in recent months over unfair pricing of drugs from newly acquired companies, even drawing the ire of candidates of the 2016 presidential election. That type of attention has driven the stock price down and even prompted presidential candidate Hillary Clinton to make a call for prescription-drug-pricing reform as part of her election campaign.

    Whether or not that reform will actually occur remains a question that won’t be answered until after the election at the earliest and more than likely several years down the road. The more pressing question for both investors and Valeant is if the current model of growth via acquisition then selling medication at higher price points is still sustainable.

    When companies go through hard times, investors and employees will turn to leadership for guidance. Unfortunately for Valeant, this is another source of concern as CEO Michael Pearson has been forced into medical leave after being struck ill with a bad case of pneumonia.

    Valeant as a company is a great investment. The business model has worked well for the company, and given the amount of bad news the company has had over the past six months, it is arguable that the stock has suffered enough on that bad news.

    Valeant too risky for your portfolio? Here's another company to consider

    Exports of liquefied natural gas could be one of the best growth opportunities out there for long-term investors. And, we think we've identified the Canadian company to invest in. It's a global company with operations across nearly 20 countries and 70 locations. We like it so much, we've named it as 1 Top Stock for 2016 and Beyond
  8. [verwijderd] 15 februari 2016 20:09

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    inter Pipeline Ltd (TSE:IPL) announced a monthly dividend on Friday, February 19th, Analyst Ratings.Net reports. Shareholders of record on Tuesday, March 15th will be paid a dividend of 0.13 per share on Tuesday, March 15th. This represents a $1.56 annualized dividend and a yield of 7.52%. The ex-dividend date is Friday, February 19th.
    In other Inter Pipeline news, insider Christian Bayle bought 14,982 shares of the business’s stock in a transaction on Wednesday, December 9th. The stock was purchased at an average price of C$20.48 per share, for a total transaction of C$306,900.28. Also, insider Stephen James Arsenych bought 1,100 shares of the business’s stock in a transaction on Friday, November 20th. The shares were acquired at an average price of C$23.93 per share, with a total value of C$26,323.00.
    IPL has been the topic of several research analyst reports. Canaccord Genuity decreased their price objective on shares of Inter Pipeline to C$28.50 and set a “buy” rating on the stock in a research note on Friday, October 23rd. RBC Capital reduced their target price on shares of Inter Pipeline from C$33.00 to C$30.00 and set an “outperform” rating on the stock in a research report on Monday, November 9th. Raymond James reduced their target price on shares of Inter Pipeline to C$27.00 and set a “market perform” rating on the stock in a research report on Tuesday, December 22nd. National Bank Financial reduced their target price on shares of Inter Pipeline from C$33.00 to C$28.00 in a research report on Monday, January 25th. Finally, CIBC reduced their target price on shares of Inter Pipeline from C$33.00 to C$30.00 in a research report on Monday, February 1st. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of C$30.39.


    Shares of Inter Pipeline (TSE:IPL) opened at 20.75 on Friday. Inter Pipeline has a one year low of $18.43 and a one year high of $34.36. The company’s 50 day moving average is $21.34 and its 200 day moving average is $24.09. The company has a market capitalization of $6.98 billion and a price-to-earnings ratio of 18.68.
    Inter Pipeline Ltd. (TSE:IPL) owns and operates energy infrastructure assets located in western Canada and Europe. Inter Pipeline operates in four segments: oil sands transportation business, conventional oil pipelines business, natural gas liquids (NGL) extraction business and the bulk liquid storage business.
429 Posts
Pagina: «« 1 ... 12 13 14 15 16 ... 22 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.092
AB InBev 2 5.525
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.810
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.757
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.757
Aedifica 3 923
Aegon 3.258 322.942
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.895
Agfa-Gevaert 14 2.051
Ahold 3.538 74.343
Air France - KLM 1.025 35.192
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.043
Alfen 16 25.004
Allfunds Group 4 1.510
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.825
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.477
AMG 971 133.922
AMS 3 73
Amsterdam Commodities 305 6.698
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.027
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.787
Arcelor Mittal 2.034 320.836
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.328
Aroundtown SA 1 220
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.421
ASML 1.766 108.589
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 521
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.688
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.406